Use of complementary and alternative medical therapy by patients with primary brain tumors

  • Terri S. Armstrong
  • Mark R. Gilbert


The use of complementary and alternative medicine (CAM) is increasing. CAM includes mind-body interventions, biologically based therapies, energy therapies, and body-based methods. Primary brain tumors arise within the brain and have a poor prognosis when malignant. Even patients with benign tumors suffer neurologic and systemic symptoms as a result of the tumor or its treatment. CAM is used by 30% of brain tumor patients, who often do not report its use to their physician. Herbal medicines may affect the metabolism of prescribed medications or produce adverse effects that may be attributed to other causes. In patients with systemic cancer, mind-body modalities such as meditation and relaxation therapy have been shown to be helpful in reducing anxiety and pain; acupuncture and hypnotherapy may also reduce both pain and nausea. Recent preclinical studies have reported that ginseng, Scutellaria baicalensis, and Angelica sinensis may promote apoptosis of tumor cells or exercise antiangiogenic effects. Further studies are needed to evaluate the impact of CAM on symptom control or tumor growth in this vulnerable patient population.


Brain Tumor Primary Brain Tumor Rain Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2005.Google Scholar
  2. 2.
    Armstrong T, Cohen MZ, Hess KR, et al.: Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage 2006, 32:148–154.PubMedCrossRefGoogle Scholar
  3. 3.
    Gonzalez J, Gilbert MR: Treatment of astrocytomas. Curr Opin Neurol 2005, 18:632–638.PubMedCrossRefGoogle Scholar
  4. 4.
    Burger C, Heinz ER, Shibata T, et al.: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988, 68:698–704.PubMedGoogle Scholar
  5. 5.
    Stupp R, Mason W, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996.PubMedCrossRefGoogle Scholar
  6. 6.
    Butler JM, Rapp SR, Shaw EG: Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 2006, 7:517–523.PubMedCrossRefGoogle Scholar
  7. 7.
    National Center for Complementary and Alternative Medicine: CAM basics. Available at Accessed on December 31, 2007.
  8. 8.
    Mansky J, Wallerstedt DB: Complementary medicine in palliative care and cancer symptom management. Cancer J 2006, 12:425–431.PubMedGoogle Scholar
  9. 9.
    Eisenberg DM: The Institute of Medicine report on complementary and alternative medicine in the United States—personal reflections on its content and implications. Altern Ther Health Med 2005, 11:10–15.PubMedGoogle Scholar
  10. 10.
    Eisenberg DM, Kaptchuk TJ, Laine C, et al.: Complementary and alternative medicine—an Annals series. Ann Intern Med 2001, 135:208.PubMedGoogle Scholar
  11. 11.
    Barnes M, Powell-Griner E, McFann K, et al.: Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004, 343:1–19.PubMedGoogle Scholar
  12. 12.
    Kuo GM, Hawley ST, Weiss LT, et al.: Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. BMC Complement Altern Med 2004, 4:18.PubMedCrossRefGoogle Scholar
  13. 13.
    Lerner IJ, Kennedy BJ: The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 1992, 42:181–191.PubMedCrossRefGoogle Scholar
  14. 14.
    Cassileth BR: Overview of alternative/complementary medicine. Cancer Pract 1998, 6:243–245.PubMedCrossRefGoogle Scholar
  15. 15.
    Bennett M, Lengacher C: Use of complementary therapies in a rural cancer population. Oncol Nurs Forum 1999, 26:1287–1294.PubMedGoogle Scholar
  16. 16.
    Sparber A, Bauer L, Curt G, et al.: Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 2000, 27:623–630.PubMedGoogle Scholar
  17. 17.
    Fox S, Laws ER Jr, Anderson F Jr, Farace E: Complementary therapy use and quality of life in persons with high-grade gliomas. J Neurosci Nurs 2006, 38:212–220.PubMedCrossRefGoogle Scholar
  18. 18.
    Verhoef MJ, Hagen N, Pelletier G, et al.: Alternative therapy use in neurologic diseases: use in brain tumor patients. Neurology 1999, 52:617–622.PubMedGoogle Scholar
  19. 19.
    Markowitz JS, Donovan JL, DeVane CL, et al.: Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003, 290:1500–1504.PubMedCrossRefGoogle Scholar
  20. 20.
    Fetell MR, Grossman SA, Fisher JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997, 15:3121–3128.PubMedGoogle Scholar
  21. 21.
    Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940–2949.PubMedGoogle Scholar
  22. 22.
    Tasaki K, Maskarinec G, Shumay DM, et al.: Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients’ perspectives. Psychooncology 2002, 11:212–220.PubMedCrossRefGoogle Scholar
  23. 23.
    Hammer MR, Jonas WB: Managing social conflict in complementary and alternative medicine research: the case of antineoplastons. Integr Cancer Ther 2004, 3:59–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Cassileth B, Trevisan C, Gubili J: Complementary therapies for cancer pain. Curr Pain Headache Rep 2007, 11:265–269.PubMedCrossRefGoogle Scholar
  25. 25.
    Deng G, Cassileth BR, Yeung KS: Complementary therapies for cancer-related symptoms. J Support Oncol 2004, 2:419–426; discussion 427–429.PubMedGoogle Scholar
  26. 26.
    Miller M, Boyer MJ, Butow N, et al.: The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost. Support Care Cancer 1998, 6:337–347.PubMedCrossRefGoogle Scholar
  27. 27.
    Tsai NM, Lin SZ, Lee CC, et al.: The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 2005, 11:3475–3484.PubMedCrossRefGoogle Scholar
  28. 28.
    Ye YN, Koo MW, Li Y, et al.: Angelica sinensis modulates migration and proliferation of gastric epithelial cells. Life Sci 2001, 68:961–968.PubMedCrossRefGoogle Scholar
  29. 29.
    Ye YN, Liu ES, Shin VY, et al.: A mechanistic study of proliferation induced by Angelica sinensis in a normal gastric epithelial cell line. Biochem Pharmacol 2001, 61:1439–1448.PubMedCrossRefGoogle Scholar
  30. 30.
    Ye YN, So HL, Liu ES, et al.: Effect of polysaccharides from Angelica sinensis on gastric ulcer healing. Life Sci 2003, 72:925–932.PubMedCrossRefGoogle Scholar
  31. 31.
    Scheck AC, Perry K, Hank NC, et al.: Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells. BMC Complement Altern Med 2006, 6:27.PubMedCrossRefGoogle Scholar
  32. 32.
    Chung C, Park JB, Bae KH: Pharmacological effects of methanolic extract from the root of Scutellaria baicalensis and its flavonoids on human gingival fibroblast. Planta Med 1995, 61:150–153.PubMedCrossRefGoogle Scholar
  33. 33.
    Bigler D, Gulding KM, Dann R, et al.: Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. Oncogene 2003, 22:1261–1272.PubMedCrossRefGoogle Scholar
  34. 34.
    Bonham M, Posakony J, Coleman I, et al.: Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin Cancer Res 2005, 11:3905–3914.PubMedCrossRefGoogle Scholar
  35. 35.
    Yue Y, Mak NK, Cheng YK, et al.: Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med 2007, 2:6.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of Integrative Nursing CareUniversity of Texas Health Science Center School of NursingHoustonUSA

Personalised recommendations